Cancer Research 64, , , . doi:
© 2009 American Association for Cancer Research
(Click the button above to download this figure into PowerPoint for use in presentations. Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Note: Users are permitted to download figures from AACR journals into
PowerPoint for use in educational presentations, provided that the citation
and copyright information are displayed on the slide. Commercial use of
these images or reproduction of the images in any other form requires
written permission from the AACR. For more information on permission
requests, send an e-mail message to permissions{at}aacr.org.
Click on image to view larger version.
Fig. 6. Antitumor effect of 8H9(Fv)-PE38 in severe combined immunodeficient mice. Groups of animals received injection with 2 x 106 MCF-7 cells (A-D) or OHS-M1 cells (E and F) on day 0. On day 4, tumors reached a size of 50 mm3. Animals were treated i.v. on days 4, 6, and 8 with 0.075 (
) and 0.15 mg/kg (
) 8H9(scFv)-PE38 in Dulbecco’s modified PBS containing 0.2% HSA or 0.075 (
) and 0.15 mg/kg (
) 8H9(dsFv)-PE38 in Dulbecco’s modified PBS (0.2% HSA). Control groups received diluent alone (
) or M1(dsFv)-PE38 (
), which is an immunotoxin against CD25. No deaths were observed at these doses. Comparison of tumor size (*) between and , , or gives P < 0.05. Data are expressed as the mean ± SD (n = 5 or 10).
